Literature DB >> 19501259

Synthesis and anti-Hantaan virus activity of N(1)-3-fluorophenyl-inosine.

Dong-Hoon Chung1, J Jacob Strouse, Yanjie Sun, Jeffrey B Arterburn, William B Parker, Colleen B Jonsson.   

Abstract

As part of an ongoing effort to develop new antiviral nucleoside analogs, our interest was drawn to n class="Chemical">N(1)-aryl purines as a novel structural class and potential scaffold for drug discovery. Herein, we describe the synthesis of N(1)-3-fluorophenyl-inosine (FPI) and N(1)-3-fluorophenyl-hypoxanthine (FP-Hx) and their antiviral activity against hantaviruses. The EC(50) for FPI and FP-Hx were 94 and 234microM, respectively, against Hantaan virus. FPI was not toxic to mammalian cells at concentrations that exhibited antiviral activity. Analysis of its metabolism revealed a low conversion of FPI in Vero E6 or human cells to a 5'-triphosphate, and it was a poor substrate for human purine nucleoside phosphorylase. Further, the compound did not alter GTP levels indicating FPI does not inhibit inosine monophosphate dehydrogenase. With respect to the virus, FPI did not decrease viral RNA levels or increase the mutation frequency of the viral RNA. This suggests that the antiviral activity of FPI might be solely due to the interaction of FPI or its metabolites with viral or host proteins involved in post-replication events that would affect the levels of infectious virus released. Synthesis of other compounds structurally similar to FPI is warranted to identify more potent agents that selectively abrogate production of infectious virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501259      PMCID: PMC2796853          DOI: 10.1016/j.antiviral.2009.03.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  22 in total

1.  Accumulation of terminally deleted RNAs may play a role in Seoul virus persistence.

Authors:  B J Meyer; C Schmaljohn
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis.

Authors:  M E Jones
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

3.  Serological evidence of Hantaan virus infection in the United States.

Authors:  R Yanagihara; C T Chin; M B Weiss; D C Gajdusek; A R Diwan; J B Poland; K T Kleeman; C M Wilfert; G Meiklejohn; W P Glezen
Journal:  Am J Trop Med Hyg       Date:  1985-03       Impact factor: 2.345

4.  Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.

Authors:  Gregory J Mertz; Lil Miedzinski; Diane Goade; Andrew T Pavia; Brian Hjelle; Christine O Hansbarger; Howard Levy; Frederick T Koster; Kenneth Baum; Adeline Lindemulder; Wenquan Wang; Laura Riser; Humberto Fernandez; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-11       Impact factor: 9.079

5.  Inhibition of inosinic acid dehydrogenase by 8-substituted purine nucleotides.

Authors:  E B Skibo; R B Meyer
Journal:  J Med Chem       Date:  1981-10       Impact factor: 7.446

6.  Inhibitors of inosinic acid dehydrogenase. 2-Substituted inosinic acids.

Authors:  C G Wong; R B Meyer
Journal:  J Med Chem       Date:  1984-04       Impact factor: 7.446

7.  Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus.

Authors:  Dong-Hoon Chung; Sidath C Kumarapperuma; Yanjie Sun; Qianjun Li; Yong-Kyu Chu; Jeffrey B Arterburn; William B Parker; Jeffrey Smith; Kristin Spik; Harish N Ramanathan; Connie S Schmaljohn; Colleen B Jonsson
Journal:  Antiviral Res       Date:  2008-03-17       Impact factor: 5.970

8.  Persistent Sin Nombre virus infection in the deer mouse (Peromyscus maniculatus) model: sites of replication and strand-specific expression.

Authors:  Jason Botten; Katy Mirowsky; Donna Kusewitt; Chunyan Ye; Keith Gottlieb; Joseph Prescott; Brian Hjelle
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

Authors:  L E Chapman; G J Mertz; C J Peters; H M Jolson; A S Khan; T G Ksiazek; F T Koster; K F Baum; P E Rollin; A T Pavia; R C Holman; J C Christenson; P J Rubin; R E Behrman; L J Bell; G L Simpson; R F Sadek
Journal:  Antivir Ther       Date:  1999

10.  Ribavirin causes error catastrophe during Hantaan virus replication.

Authors:  William E Severson; Connie S Schmaljohn; Ali Javadian; Colleen B Jonsson
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  2 in total

Review 1.  Human pathogenic hantaviruses and prevention of infection.

Authors:  Detlev H Krüger; Günther Schönrich; Boris Klempa
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Authors:  Monica Ogg; Colleen B Jonsson; Jeremy V Camp; Jay W Hooper
Journal:  Viruses       Date:  2013-11-08       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.